Dissou Affolabi, Ph.D.
Affiliations: | 2009 | Universiteit Antwerpen (Belgium) |
Area:
Microbiology BiologyGoogle:
"Dissou Affolabi"Parents
Sign in to add mentor| Luc Kestens | grad student | 2009 | Universiteit Antwerpen (Belgium) | |
| (Development of simple and inexpensive tools for the control of mycobacterial diseases in a low-resource country.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Badoum G, Ouédraogo AR, Fiogbé AA, et al. (2024) An Overview of the Management of Drug-Resistant Tuberculosis in Six French-Speaking African Countries from 2018 to 2022. Tropical Medicine and Infectious Disease. 9 |
| Snobre J, Gasana J, Ngabonziza JCS, et al. (2024) Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial. Bmj Open. 14: e078379 |
| Diallo AB, Edem VF, Fiogbe A, et al. (2024) Diagnostic accuracy of Xpert® MTB/RIF Ultra for childhood tuberculosis in West Africa - a multicentre pragmatic study. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases |
| Trajman A, Adjobimey M, Bastos ML, et al. (2022) GeneXpert or chest-X-ray or tuberculin skin testing for household contact assessment (GXT): protocol for a cluster-randomized trial. Trials. 23: 624 |
| Ngabonziza JCS, Rigouts L, Torrea G, et al. (2022) Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 27: 100299 |
| Ngabonziza JCS, Decroo T, Migambi P, et al. (2020) Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. The Lancet. Microbe. 1: e74-e83 |
| Koura KG, Harries AD, Fujiwara PI, et al. (2020) COVID-19 in Africa: community and digital technologies for tuberculosis management. International Journal of Tuberculosis and Lung Disease. 24: 863-865 |
| Semuto Ngabonziza JC, Van Deun A, Migambi P, et al. (2020) Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis. The American Journal of Tropical Medicine and Hygiene |
| Ngabonziza JS, Habimana YM, Decroo T, et al. (2020) Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 24: 329-339 |
| Gbadebo OJ, Charles A, Affolabi D, et al. (2020) Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients attending Chest Clinics in Osun-State, Nigeria. Current Pharmaceutical Biotechnology |